Luca Pani, MD, is an Italian and American Citizen, Full Professor of Pharmacology and Clinical Pharmacology, University of Modena and Reggio Emilia in Italy, and Professor of Clinical Psychiatry, University of Miami, USA. Luca is the Chief Advisor for Relmada Therapeutics; a late-stage biotech company focused on addressing diseases of the central nervous system (CNS), based in Coral Gables, FL, USA; he Chief Innovation and Regulatory Officer to Netramark an Artificial Intelligence technology company that support clinical trials analysis leveraging cutting-edge technology, based in Toronto, Canada.
From 2017 to 2021, Luca has served as the Chief Scientific Officer of INPECO SA, the most significant world Lab Automation Company based in Novazzano, Switzerland. He was most recently appointed as a Member of the new Scientific Committee of the Human Technopole Foundation, Italy’s new research institute for life sciences whose mission is to improve human health and well-being, including focusing on healthy aging.
Luca Pani is the coordinator of FACILITATE (FrAmework for ClinIcaL triaL particIpants’ daTA reutilization for a fully Transparent and Ethical ecosystem), the last IMI-2 project funded by the European Commission (Jan 2022- Dec 2025).
As the former Director-General of the Italian Medicines Agency (AIFA, 2011-2016) and former member of the Board of Directors of the Committee for Human Medicines (CHMP) and the Scientific Advice Working Party (SAWP) for the European Medicines Agency (EMA) in London (2010-2017), he was elected as Chair of the EU Telematics Committee (2013-2016) overlooking the EMA databases transition plan.